Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 7 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 10 patents granted in the last 365 days
Shanghai Hengrui Pharmaceutical Co., Ltd. has 9 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 9 distinct examiners across 8 distinct art units. This distribution shows that the portfolio is broadly dispersed among examiners, while at least one art unit handles more than one matter.
SANDERSON, LEE E is the busiest examiner, with 1 pending matter. No examiner has a larger listed concentration, so examiner-specific monitoring should cover all active matters. The art-unit distribution makes it useful to compare responses within the same unit while maintaining separate strategies for different examiners.
For prosecution management, a centralized claim and amendment record can help identify recurring biotechnology issues without assuming that one examiner’s approach applies across the portfolio. The number of active matters also supports staged review of response deadlines, interview opportunities, and continuation strategy where relevant to the individual files.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 3 (38%) |
| Double-patenting only | 1 (12%) |
| Double-patenting + other | 2 (25%) |
| Multi-statute (no §101) | 1 (12%) |
| No statute on record | 1 (12%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SANDERSON, LEE E | 1 | 45.2% | +45.2% |
| SZNAIDMAN, MARCOS L | 1 | 37.4% | +16.1% |
| ALLEN, MARIANNE P | 1 | 60.1% | +18.4% |
| SKOKO III, JOHN JOSEPH | 1 | 53.0% | +55.2% |
| BELYAVSKYI, MICHAIL A | 1 | 63.9% | +28.0% |
| BORALSKY, LUKE ALAN | 1 | 66.7% | +44.4% |
| BRISTOL, LYNN ANNE | 1 | 63.4% | +39.8% |
| HUYNH, PHUONG N | 1 | 65.8% | +53.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18284009 | TRUNCATED TACI POLYPEPTIDE AND FUSION PROTEIN AND USE THEREOF | BRISTOL, LYNN ANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18284654 | TETRAHYDRONAPHTHALENE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | BORALSKY, LUKE ALAN | 14d |
| 18772865 | METHOD FOR PREPARING BENZOFURAN DERIVATIVE | SANDERSON, LEE E | — |
| 18703712 | NITROGEN-CONTAINING TETRACYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | SZNAIDMAN, MARCOS L | — |
| 18694365 | ANTI-KLB ANTIBODIES AND USES | ALLEN, MARIANNE P | — |
| 18580602 | PHARMACEUTICAL COMPOSITION CONTAINING ANTI-TROP2 ANTIBODY DRUG CONJUGATE AND ITS APPLICATION | SKOKO III, JOHN JOSEPH | — |
| 18290132 | ANTIGEN BINDING MOLECULE SPECIFICALLY BINDING TO RANKL AND NGF, AND MEDICAL USE THEREOF | BELYAVSKYI, MICHAIL A | — |
| 18284009 | TRUNCATED TACI POLYPEPTIDE AND FUSION PROTEIN AND USE THEREOF | BRISTOL, LYNN ANNE | — |
| 17782980 | ANTI-CLAUDIN ANTIBODY-DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOF | HUYNH, PHUONG N | — |
| Art Unit | Apps |
|---|---|
| 1643 | 2 |
| 3991 | 1 |
| 1628 | 1 |
| 1647 | 1 |
| 1644 | 1 |
| 1624 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18772865 | METHOD FOR PREPARING BENZOFURAN DERIVATIVE | SANDERSON, LEE E | 3991 | Other | Non-Final OA | — | Pending | Jul 15, 2024 |
| 18703712 | NITROGEN-CONTAINING TETRACYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | SZNAIDMAN, MARCOS L | 1628 | §112 | Non-Final OA | — | Pending | Apr 22, 2024 |
| 18694365 | ANTI-KLB ANTIBODIES AND USES | ALLEN, MARIANNE P | 1647 | §112 | Non-Final OA | — | Pending | Mar 21, 2024 |
| 18580602 | PHARMACEUTICAL COMPOSITION CONTAINING ANTI-TROP2 ANTIBODY DRUG CONJUGATE AND ITS APPLICATION | SKOKO III, JOHN JOSEPH | 1643 | §112DP | Non-Final OA | — | Pending | Jan 18, 2024 |
| 18290132 | ANTIGEN BINDING MOLECULE SPECIFICALLY BINDING TO RANKL AND NGF, AND MEDICAL USE THEREOF | BELYAVSKYI, MICHAIL A | 1644 | §103§112DP | Non-Final OA | — | Pending | Nov 09, 2023 |
| 18284654 | TETRAHYDRONAPHTHALENE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | BORALSKY, LUKE ALAN | 1624 | §112 | Final Rejection | 14d | Pending | Sep 28, 2023 |
| 18284009 | TRUNCATED TACI POLYPEPTIDE AND FUSION PROTEIN AND USE THEREOF | BRISTOL, LYNN ANNE | 1643 | §102§103§112Other | Non-Final OA | — | Pending | Sep 25, 2023 |
| 17782980 | ANTI-CLAUDIN ANTIBODY-DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOF | HUYNH, PHUONG N | 1641 | DP | Non-Final OA | — | Pending | Jun 06, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShanghai Hengrui Pharmaceutical Co., Ltd. has 8 pending office actions as of October 2026, spread across 7 art units and 8 examiners.
Lee E Sanderson has the most, with 1 of Shanghai Hengrui Pharmaceutical Co., Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
